Company Profile · Healthcare

Royalty Pharma Plc

RPRX · US
Industry
生物制药特许权
Exchange
US
Country
USA
IPO date
Mar 25, 1993
Employees
100
Website
www.royaltypharma.com
Current Price
$57.16
Live · Oct 4, 2026
Fair Buy
≤ $40
Margin-of-safety entry
Baillie Growth Score
50/100
Medium
Buffett Score
58/100
Medium
Intrinsic Value · Three-Tier Range Current price $57.16 Live · Within the fair intrinsic-value range

Composite valuation range · conservative $36–$40 / fair $52–$66 / optimistic $84–$90. At $57.16, Within the fair intrinsic-value range.

At publication $58.41 (Sep 20, 2026)

Financial snapshot
Market cap$33.03B
Revenue (TTM)$2.54B
EBITDA$1.56B
Profit margin32.02%
ROE13.97%
P/E (TTM)30.9
Forward P/E29.41
PEG1.34
EPS$1.85
Dividend yield1.58%
52-week range$34.56 – $64.38
Analyst target$65.13
Analyst rating4.5 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

About the company

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

Research on this stock
50/100 Hold Royalty Pharma: $3.254bn of Portfolio Receipts and 48% Deal Share Meet a 24% Expiry Wall by 2030 and a $58.41 Price That Already Pays for the Platform Royalty Pharma is a specialty-finance platform whose loan book is denominated in molecules: it buys contractual percentages of other companies' drug sales, funds late-stage development in exchange for synthetic royalties, and collects near the top of the income statement while somebody else carries the commercial cost. 2025 Portfolio Receipts were $3.254bn against only $288m of cash operating and professional costs, and the company sourced 48% of announced biopharma-royalty transaction value over 2020-2025, but roughly 24% of 2025 Royalty Receipts sits on products whose royalty duration substantially ends by 2030, and hitting the $4.7bn 2030 target needs $2.0-2.5bn of deployment every year. Rating Hold: at $58.41 the shares are near 11.6 times estimated 2026 Portfolio Cash Flow but 19-23 times owner earnings once $1.1-1.4bn of replacement deployment is charged as economic maintenance, above the $46-50 conservative value, so the report waits for $36-40 before committing new capital. Royalty Pharma plcRPRX · US生物制药特许权Sep 20, 2026